Submitted by Johnson & Johnson
This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.
Each week our host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to help bring an end to the deadly pandemic.
This week in Episode 3, Lisa Ling interviews National Academies member and University of Connecticut professor Cato Laurencin, M.D., Ph.D., to learn what his new coronavirus study reveals. Plus, what’s needed to mass-produce a vaccine.
Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. This year, we celebrate 126 years of embracing research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work in more than 250 operating companies in 60 countries throughout the world. The passion and commitment of our people yield innovations that further minimize our impact on the planet, drive new alliances to address major health challenges in developing and developed countries, and help to create economic opportunity for people. Improving human health and well-being is our crucial mission and the ultimate measure of upholding our responsibility now and for generations to come.
At Johnson & Johnson, our top priority is health-health of people and the planet. That's why we set aggressive corporate wide goals to reduce our environmental impact, outlined in our Healthy Future 2015 goals. To this end, we established the proprietary Earthwards® process for developing and marketing greener products through lifecycle analysis. Every Earthwards® recognized product must achieve a greater than 10 percent improvement in at least three of the seven goal areas:
More from Johnson & Johnson